Bangladesh Medical Device Regulator: DGDA and Its Six Powers

1. Key takeaways

In Bangladesh the single competent authority for medical devices, in vitro diagnostic reagents and the software attached to them is the Directorate General of Drug Administration (DGDA), which reports to the Ministry of Health and Family Welfare (MoHFW) and sits at Aushad Bhaban, Mohakhali, Dhaka-1212. The same body holds six distinct powers: product registration, import intent approval, customs clearance release, fixation of the maximum retail price (MRP), vigilance monitoring and market inspection. Because all six powers are concentrated in one institution, a failure at any single point does not remain local. It travels. A file that is technically complete can still stall at import approval, and a cleared consignment can sit in a warehouse because the price has not yet been fixed. Companies that plan only for the registration certificate therefore tend to arrive at the market late, with stock they are not yet permitted to sell.

• One regulator, six powers. Registration is the first gate, never the last one.
• Devices, diagnostic reagents and software are regulated as drugs, so pharmaceutical vocabulary and administrative habits carry over into device files without modification.
• Products sit in four classes, Class A to Class D, and the first classification judgement is made by the applicant rather than the authority.
• Technical judgement is exercised by a committee, not by a single officer, which ties project timing to meeting schedules.
• A certificate is not a licence to sell. Import intent approval, customs clearance and MRP fixation are separate administrative acts.

2. Legal basis

The mandate is statutory rather than administrative convenience. The Drug and Cosmetics Act, 2023 (Act No. 29 of 2023), in force from 18 September 2023, is the parent law and replaced both the Drugs Act, 1940 (Act No. XXIII of 1940) and the Drugs (Control) Ordinance, 1982 (Ordinance No. VIII of 1982). Operational detail for devices is set out in the DGDA Medical Device Registration Guidelines, published as Device Classification v 1.0, which allocate the assessment routes by class and describe the post-market duties that follow registration.

3. Expert insights

Insight one: six powers in one hand is the structural difference between Bangladesh and Southeast Asian markets. Registration authorities in Vietnam, Thailand and Singapore generally govern product access only, while import and pricing sit in separate systems. The DGDA governs from registration all the way through to the retail price and the shelf. The practical consequence is blunt: a certificate in hand does not mean the product can be sold. Three further formalities remain, namely import intent approval, customs clearance and MRP fixation, and until the price is fixed the goods cannot leave the warehouse even though they have cleared.

Insight two: devices were written into the definition of a drug, so the pharmaceutical administrative system applies directly. This explains why Bangladeshi device files contain terms such as Recipe Approval and Master Formula, vocabulary that plainly originates in medicines regulation. Manufacturers who do not understand this layer often read the terminology as a translation error, when in fact it is the direct result of how the statute was drafted. The regulator did not build a device administration and then borrow pharmaceutical language. It extended the existing pharmaceutical administration to devices, and the language came with it.

Insight three: technical judgement rests with a committee rather than an individual. Section 8 of the guidelines states that the device expert committee is constituted by the government and operates as a technical sub-committee of the Drug Control Committee. That arrangement is the organisational basis for the quarterly meeting cycle described in the twelfth article of this series. Project duration is therefore not set by the intake window but by the committee calendar. A file submitted one week after a sitting waits roughly a quarter before it is considered at all, and no amount of document quality shortens that interval. Section 9 complements the arrangement with safeguard powers allowing temporary withdrawal, prohibition or restriction of marketing, which means the same committee logic continues after approval.

4. Practical recommendations

• Map the six powers onto named parties before signing anything. Registration, import intent approval, customs clearance, MRP filing, vigilance reporting and market inspection response should each have an owner identified in writing.
• Write the allocation into an annex to the local cooperation agreement rather than a single sentence stating that the partner handles registration matters. A generic clause is the most common source of later dispute, because it leaves five of the six duties unassigned.
• Treat the certificate, the import permission and the price approval as three separate deliverables with three separate timelines when building the project plan.
• Confirm in writing which party answers a market inspection and which party holds the original certificate, since both questions surface only after the product is on the shelf.
• Record the classification judgement and its reasoning at the outset, so that a later challenge at the recipe approval stage can be answered with a document rather than a recollection.

5. Verification checklist

• □ Confirmed that the competent authority for the project is the DGDA, under MoHFW, at Aushad Bhaban, Mohakhali, Dhaka-1212
• □ Confirmed under the Drug and Cosmetics Act, 2023 that the product falls within the device definition
• □ Allocated the six duties of registration, import intent approval, customs clearance, MRP, vigilance and inspection in the cooperation agreement
• □ Completed a preliminary product class determination under §4.4 of the guidelines
• □ Confirmed whether BSTI or NCL is involved in this project, with any open items listed as pending verification

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com